|
1
|
Bongartz LG, Braam B, Gaillard CA, Cramer
MJ, Goldschmeding R, Verhaar MC, Doevendans PA and Joles JA: Target
organ cross talk in cardiorenal syndrome: Animal models. Am J
Physiol Renal Physiol. 303:F1253–F1263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hou FF and Yang X: Advances in the
management of acute cardiorenal syndrome in China: Biomarkers for
predicting development and outcomes. Kidney Dis (Basel). 2:145–150.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niizuma S, Iwanaga Y, Yahata T and
Miyazaki S: Renocardiovascular biomarkers: From the perspective of
managing chronic kidney disease and cardiovascular disease. Front
Cardiovasc Med. 4:102017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgenthaler NG, Struck J, Jochberger S
and Dünser MW: Copeptin: Clinical use of a new biomarker. Trends
Endocrinol Metab. 19:43–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morawiec B and Kawecki D: Copeptin: A new
marker in cardiology. J Cardiovasc Med (Hagerstown). 14:19–25.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JS, Yang JW, Chai MH, Lee JY, Park H,
Kim Y, Choi SO and Han BG: Copeptin in hemodialysis patients with
left ventricular dysfunction. Yonsei Med J. 56:976–980. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Velho G, Bouby N, Hadjadj S, Matallah N,
Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C,
Alhenc-Gelas F, et al: Plasma copeptin and renal outcomes in
patients with type 2 diabetes and albuminuria. Diabetes Care.
36:3639–3645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Windt WA, Henning RH, Kluppel AC, Xu Y, de
Zeeuw D and van Dokkum RP: Myocardial infarction does not further
impair renal damage in 5/6 nephrectomized rats. Nephrol Dial
Transplant. 23:3103–3110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng DF, Tang SY, Hu YJ, Chen J and Yang
L: Pathophysiological model of chronic heart failure complicated
with renal failure caused by three-quarter nephrectomy and
subcutaneous injection of isoprenaline. Exp Ther Med. 5:835–839.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pang L, Lian X, Li Y, Nan L and Ma H:
Efficacy and safety of parecoxib sodium after renal
transplantation. African J Pharm Pharmacol. 5:2467–2473. 2011.
|
|
11
|
Aydin S, Eren MN, Kuloglu T, Aydin S,
Yilmaz M, Gul E, Kalayci M, Yel Y, Cakmak T and Bico S: Alteration
of serum and cardiac tissue adropin, copeptin, irisin and TRPM2
expressions in DOX treated male rats. Biotech Histochem.
90:197–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Dokkum RP, Eijkelkamp WB, Kluppel AC,
Henning RH, van Goor H, Citgez M, Windt WA, van Veldhuisen DJ, de
Graeff PA and de Zeeuw D: Myocardial infarction enhances
progressive renal damage in an experimental model for cardio-renal
interaction. J Am Soc Nephrol. 15:3103–3110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Entin-Meer M, Ben-Shoshan J,
Maysel-Auslender S, Levy R, Goryainov P, Schwartz I, Barshack I,
Avivi C, Sharir R and Keren G: Accelerated renal fibrosis in
cardiorenal syndrome is associated with long-term increase in urine
neutrophil gelatinase-associated lipocalin levels. Am J Nephrol.
36:190–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu S, Kompa AR, Kumfu S, Nishijima F,
Kelly DJ, Krum H and Wang BH: Subtotal nephrectomy accelerates
pathological cardiac remodeling post-myocardial infarction:
implications for cardiorenal syndrome. Int J Cardiol.
168:1866–1880. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lipinski MJ, Escárcega RO, D'Ascenzo F,
Magalhães MA, Baker NC, Torguson R, Chen F, Epstein SE, Miró O,
Llorens P, et al: A systematic review and collaborative
meta-analysis to determine the incremental value of copeptin for
rapid rule-out of acute myocardial infarction. Am J Cardiol.
113:1581–1591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boeckel JN, Oppermann J, Anadol R,
Fichtlscherer S, Zeiher AM and Keller T: Analyzing the release of
copeptin from the heart in acute myocardial infarction using a
transcoronary gradient model. Sci Rep. 6:208122016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Broessner G, Hasslacher J, Beer R, Lackner
P, Lehner GF, Harler U, Schiefecker A, Helbok R, Pfausler B,
Hammerer-Lercher A and Joannidis M: Outcome prediction and
temperature dependency of MR-proANP and copeptin in comatose
resuscitated patients. Resuscitation. 89:75–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schrimpf C, Gillmann HJ, Sahlmann B,
Meinders A, Larmann J, Wilhelmi M, Aper T, Rustum S, Lichtinghagen
R, Theilmeier G and Teebken OE: Renal function interferes with
copeptin in prediction of major adverse cardiac events in patients
undergoing vascular surgery. PLoS One. 10:e01230932015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baumert M, Surmiak P, Więcek A and
Walencka Z: Serum NGAL and copeptin levels as predictors of acute
kidney injury in asphyxiated neonates. Clin Exp Nephrol.
21:658–664. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palazzuoli A, Ruocco G, Pellegrini M,
Martini S, Del Castillo G, Beltrami M, Franci B, Lucani B and Nuti
R: Patients with cardiorenal syndrome revealed increased
neurohormonal activity, tubular and myocardial damage compared to
heart failure patients with preserved renal function. Cardiorenal
Med. 4:257–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beltrami M, Ruocco G, Ibrahim A, Lucani B,
Franci B, Nuti R and Palazzuoli A: Different trajectories and
significance of B-type natriuretic peptide, congestion and acute
kidney injury in patients with heart failure. Intern Emerg Med.
12:593–603. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Santos-Araújo C, Leite-Moreira A and
Pestana M: Clinical value of natriuretic peptides in chronic kidney
disease. Nefrologia. 35:227–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
